Upcoming Meeting

2021 IBCN Update Series
September 25, October 30, and December 4

1600-1730 CET 


Dear Friends & Colleagues,


We are going to have to cancel our virtual and in-person IBCN meeting this year. Instead we are excited the IBCN Update Series on  September 25, October 30, and December 4th from 1600-1730 CET. 

Please mark your calendars and we will forward more details about the series and links closer to that date. We are still considering an in-person meeting in Montreal for 2022.

Please remember: The IBCN Update Series is only open to members. If you have not registered yourself as a member and paid your dues (possible now by PayPal on IBCN webpage), please contact us.

IBCN Update Series

September 25 1600-1730 CET

IBCN Update on ctDNA

Moderator: Tilman Todenhöfer

1600 ctDNA: Molecular residual disease and treatment response measurements

  • Lars Dyrskjøt


1615 ctDNA: Insights into biology of urothelial carcinoma

  • Alex Wyatt


1630 ctDNA in the clinic and clinical trials

  • Matt Galsky


1645 Panel discussion with Q&A


October 30 IBCN 1600-1730 CET

Update on Bladder Preservation after Neoadjuvant Therapy

Moderator: Ashish Kamat


1600 Clinical staging after NAC

  • Roland Seiler


1610 Abstract presentation-“Experience with bladder sparing after clinical complete response to neoadjuvant chemotherapy”

  • Harry Herr


1615 Biology of DNA Damage Repair Gene Alterations

  • Kent Mouw


1630 Marker driven bladder preservation – clinical trial update

  • Gopa Iyer


1645 Panel discussion with Q&A


December 4th 1600-1730 CET

IBCN Update on Biology of BCG Response

Moderator: Lars Dyrskjøt


1600 BCG immunology and sexual dimorphism in bladder immunity

  • Molly Ingersoll


1615 Somatic features of response to BCG

  • David Müller


1625 Transcriptomic correlates to BCG response

  • Tahlita Zuiverloon


1635 Multi-omics correlates to BCG response

  • Trine Strandgaard


1645 Immunophenotyping of BCG response and resistance

  • Amir Horowitz


1700 Clinical trial update

  • Josh Meeks


1705 Panel discussion with Q&A

Looking forward to seeing you again,